Grandbrothers/iStock Editorial via Getty Images
Calico Life Sciences announced on Thursday that the U.S. Food and Drug Administration (FDA) has issued Fast Track Designation for ABBV-CLS-628, a kidney disease therapy developed by the company in partnership with AbbVie (NYSE:ABBV).
The treatment targeting autosomal dominant polycystic
